Recent federal actions under the Controlled Substances Act have advanced marijuana rescheduling through executive and administrative channels. In April 2026, the Department of Justice and DEA issued a final order moving FDA-approved marijuana products and state-licensed medical marijuana to Schedule III, effective late that month, while launching an expedited hearing process for broader changes. This followed a December 2025 presidential executive order directing rapid completion of the rulemaking originally proposed in 2024. The DEA hearing, set to begin June 29 and conclude by mid-July 2026, will evaluate evidence on shifting all forms of marijuana from Schedule I, with traders closely tracking procedural milestones, agency statements, and any shifts in legislative or judicial timelines that could accelerate or delay full implementation.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật$758,943 KL.
Mar 31, 2026
June 30
2%
December 31
24%
$758,943 KL.
June 30
$337,208 KL.
2%
December 31
$156,853 KL.
24%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent federal actions under the Controlled Substances Act have advanced marijuana rescheduling through executive and administrative channels. In April 2026, the Department of Justice and DEA issued a final order moving FDA-approved marijuana products and state-licensed medical marijuana to Schedule III, effective late that month, while launching an expedited hearing process for broader changes. This followed a December 2025 presidential executive order directing rapid completion of the rulemaking originally proposed in 2024. The DEA hearing, set to begin June 29 and conclude by mid-July 2026, will evaluate evidence on shifting all forms of marijuana from Schedule I, with traders closely tracking procedural milestones, agency statements, and any shifts in legislative or judicial timelines that could accelerate or delay full implementation.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Thị trường mở: Feb 7, 2026, 5:04 PM ET
Khối lượng
$758,943Ngày kết thúc
Mar 31, 2026Thị trường mở
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent federal actions under the Controlled Substances Act have advanced marijuana rescheduling through executive and administrative channels. In April 2026, the Department of Justice and DEA issued a final order moving FDA-approved marijuana products and state-licensed medical marijuana to Schedule III, effective late that month, while launching an expedited hearing process for broader changes. This followed a December 2025 presidential executive order directing rapid completion of the rulemaking originally proposed in 2024. The DEA hearing, set to begin June 29 and conclude by mid-July 2026, will evaluate evidence on shifting all forms of marijuana from Schedule I, with traders closely tracking procedural milestones, agency statements, and any shifts in legislative or judicial timelines that could accelerate or delay full implementation.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Khối lượng
$758,943Ngày kết thúc
Mar 31, 2026Thị trường mở
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...Recent federal actions under the Controlled Substances Act have advanced marijuana rescheduling through executive and administrative channels. In April 2026, the Department of Justice and DEA issued a final order moving FDA-approved marijuana products and state-licensed medical marijuana to Schedule III, effective late that month, while launching an expedited hearing process for broader changes. This followed a December 2025 presidential executive order directing rapid completion of the rulemaking originally proposed in 2024. The DEA hearing, set to begin June 29 and conclude by mid-July 2026, will evaluate evidence on shifting all forms of marijuana from Schedule I, with traders closely tracking procedural milestones, agency statements, and any shifts in legislative or judicial timelines that could accelerate or delay full implementation.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật
Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp